Kestrel Neuroscience is a non-profit organization dedicated to the discovery, translation, and preclinical development of therapies for frontotemporal dementia (FTD) and related neurodegenerative diseases by bringing together world-class investigators in focused, collaborative research.
Our Vision
A world in which frontotemporal dementia and related neurodegenerative diseases are treatable, curable and eventually preventable.
Our Mission
To accelerate the scientific discoveries that enable new FTD therapies to move swiftly from discovery to drug development to patients.
Our Strategy
We support collaborative, discovery-driven science to:
Identify the genetic and molecular causes of FTD and highly related disorders such as amyotropic lateral sclerosis (ALS).
Elucidate the cellular and biological mechanisms that drive neurodegeneration.
Discover, validate, and prioritize novel therapeutic targets for translation.
Kestrel advances the most promising discoveries toward preclinical development, focusing on the early stages of the drug development pipeline. Kestrel shares common founders and works alongside the Bluefield Project to Cure FTD, which advances FTD therapeutics by supporting their clinical development.